The effect of domiciliary noninvasive ventilation on clinical outcomes in stable and recently hospitalized patients with COPD: a systematic review and meta-analysis

Dretzke, Janine; Moore, David; Dave, Chirag; Mukherjee, Rahul; Price, Malcolm J; Bayliss, Sue; Wu, Xiaoying; Jordan, Rachel; Turner, Alice

doi:10.2147/copd.s104238

Cited by 35 publications

(38 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In line with the findings of the RESCUE trial, a recent meta-analysis of the effect of home NIV in COPD has reported no mortality benefit and no reduction in exacerbation frequency, with only a trend towards reduced length of stay and improved health-related QoL (38). This analysis does not take into account the results of the Chinese or UK trials and the results are unsurprising as the RESCUE study was the largest study in the meta-analysis recruiting more than 4 times the number of patients than any other included study.…”

Section: Niv In Chronic Hypercapnic Respiratory Failuresupporting

confidence: 53%

Update: non-invasive ventilation in chronic obstructive pulmonary disease

Shah¹,

D’Cruz²,

Murphy³

2018

J. Thorac. Dis.

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) remains a common cause of morbidity and mortality worldwide. Patients with COPD and respiratory failure, whether acute or chronic have a poorer prognosis than patients without respiratory failure. Non-invasive ventilation (NIV) has been shown to be a useful tool in both the acute hospital and chronic home care setting. NIV has been well established as the gold standard therapy for acute decompensated respiratory failure complicating an acute exacerbation of COPD with reduced mortality and intubation rates compared to standard therapy. However, NIV has been increasingly used in other clinical situations such as for weaning from invasive ventilation and to palliate symptoms in patients not suitable for invasive ventilation. The equivocal evidence for the use of NIV in chronic hypercapnic respiratory failure complicating COPD has recently been challenged with data now supporting a role for therapy in selected subgroups of patients. Finally the review will discuss the emerging role of high flow humidified therapy to support or replace NIV in certain clinical situation.

show abstract

Section: Niv In Chronic Hypercapnic Respiratory Failuresupporting

confidence: 53%

Update: non-invasive ventilation in chronic obstructive pulmonary disease

Shah¹,

D’Cruz²,

Murphy³

2018

J. Thorac. Dis.

View full text Add to dashboard Cite

show abstract

“… 25 However, the effects of domiciliary NIV on clinical outcomes of chronic hypercapnic COPD patients have been contradictory in studies and meta-analyses. 26 – 28 While in one study, domiciliary NIV significantly decreased hospital admissions, 29 in another it demonstrated a borderline decrease, 30 and conversely in another study, it has been demonstrated that hospital admissions are less in patients receiving standard care compared to the patients using NIV. 31 In a multicenter Italian study, low-intensity NPPV with LTOT and LTOT alone were compared, and no difference was detected in terms of hospital admissions at the end of 2-year follow-up.…”

Section: Discussionmentioning

confidence: 96%

Prospective cross-sectional multicenter study on domiciliary noninvasive ventilation in stable hypercapnic COPD patients

Yazar¹,

Özlü²,

Sarıaydın³

et al. 2018

COPD

View full text Add to dashboard Cite

BackgroundDomiciliary noninvasive ventilation (NIV) use in stable hypercarbic COPD is becoming increasingly widespread. However, treatment compliance criteria and factors related to compliance remain to be defined.MethodsThis research was designed as a prospective, cross-sectional, multicenter real-life study. Chronic hypercapnic COPD patients who were using domiciliary NIV for at least 1 year and being followed up in 19 centers across Turkey were included in the study. The patients who used NIV regularly, night or daytime and ≥5 hours/d, were classified as “high-compliance group,” and patients who used NIV irregularly and <5 hours/d as “low-compliance group.”ResultsTwo hundred and sixty-six patients with a mean age of 64.5±10.3 years were enrolled, of whom 75.2% were males. They were using domiciliary NIV for 2.8±2 years. Spontaneous time mode (p<0.001) and night use (p<0.001) were more frequent in the high-compliance group (n=163). Also, mean inspiratory positive airway pressure values of the high-compliance group were significantly higher than the low-compliance group (n=103; p<0.001). Cardiac failure (p=0.049) and obesity (p=0.01) were significantly more frequent in the high-compliance group. There were no difference between 2 groups regarding hospitalization, emergency department and intensive care unit admissions within the last year, as well as modified Medical Research Council dyspnea and COPD Assessment Test scores. With regard to NIV-related side effects, only conjunctivitis was observed more frequently in the high-compliance group (p=0.002).ConclusionDetermination of the patients who have better compliance to domiciliary NIV in COPD may increase the success and effectiveness of treatment. This highly comprehensive study on this topic possesses importance as it suggests that patient and ventilator characteristics may be related to treatment compliance.

show abstract

“…40 Recommendations for noninvasive ventilation use in patients with obstructive sleep apnea or obesity hypoventilation syndrome, although less controversial, also lack strong evidence in terms of long-term outcomes. [42][43][44] Monitoring and Follow-Up. Follow-up for patients is recommended with attention to addressing risk factors, symptoms, and exacerbations.…”

Section: Pharmacologic Managementmentioning

confidence: 99%

COPD Guidelines: A Review of the 2018 GOLD Report

Mirza

Clay

Koslow

et al. 2018

Mayo Clinic Proceedings

354

276

View full text Add to dashboard Cite

Global Strategy for the Diagnosis, Management, and Prevention of COPD 2018 is a consensus report published periodically since 2001 by an international panel of health professionals from respiratory medicine, socioeconomics, public health, and education comprising the Global Initiative for Chronic Obstructive Lung Disease (GOLD). The GOLD documents endeavor to incorporate latest evidence and expert consensus and are intended for use as "strategy documents" for implementation of effective care for chronic obstructive lung disease (COPD) on a global level. The GOLD 2018 report defines COPD as a "common, preventable and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities, usually caused by significant exposure to noxious particles or gases," with the criteria of "persistent respiratory symptoms" being a new and controversial inclusion since 2017. With the availability of newer pharmacotherapy options, treatment recommendations are made on the basis of a review of the latest literature and directed by symptom burden and health care utilization. Apart from the change in definition, a major shift in the recommendations is the exclusion of severity of airflow limitation as one of the major factors in guiding therapy. We review the salient features of the GOLD 2018 document and provide commentary on features that merit further discussion based on our clinical experience and practice as well as literature review current as

show abstract

The effect of domiciliary noninvasive ventilation on clinical outcomes in stable and recently hospitalized patients with COPD: a systematic review and meta-analysis

Cited by 35 publications

References 45 publications

Update: non-invasive ventilation in chronic obstructive pulmonary disease

Update: non-invasive ventilation in chronic obstructive pulmonary disease

Prospective cross-sectional multicenter study on domiciliary noninvasive ventilation in stable hypercapnic COPD patients

COPD Guidelines: A Review of the 2018 GOLD Report

Contact Info

Product

Resources

About